MYX mayne pharma group limited

NEXTSTELLIS® revenue was US$14.1m vs US$4.2m in FY22 with sales...

  1. 1,060 Posts.
    lightbulb Created with Sketch. 86
    NEXTSTELLIS® revenue was US$14.1m vs US$4.2m in FY22 with sales momentum building. Dispensed cycles were up 2.5x July 2023 v July 2022 and up 80% in 2HFY23 vs 1HFY23 attributable to the positive impact of our refreshed leadership and marketing strategy.2 days agoMore than 3 fold revenue growth proves the company strategy success , with 75% reduction in marketing costs YOY , with the same rate , FY24 could reach 45 m to 50 Mil THEN so yes they are on the path to profitability . all indictors are positive .Share price outlook , if after the feb update that was 97 m worse the price reached 4.9 then after the +ve update expect 6 to 7 to 8.85 as per gauldman schs analysts
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$5.03
Change
-0.170(3.27%)
Mkt cap ! $408.6M
Open High Low Value Volume
$5.20 $5.21 $5.03 $2.804M 555.6K

Buyers (Bids)

No. Vol. Price($)
2 14654 $5.03
 

Sellers (Offers)

Price($) Vol. No.
$5.14 3111 2
View Market Depth
Last trade - 16.10pm 20/06/2025 (20 minute delay) ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.